A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Exposed to Abiraterone Acetate (TOGETHER)
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms TOGETHER
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 06 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Jan 2017 Planned End Date changed from 1 Aug 2018 to 1 Apr 2018.